Binimetinib

Binimetinib (MEK162) is a small molecule inhibitor of the MEK kinase, which is part of the RAS/RAF/MEK/ERK signaling pathway. It is used to treat certain types of cancer, such as metastatic colorectal cancer and metastatic non-small cell lung cancer. It is taken as an oral tablet and is used in combination with a BRAF inhibitor or an EGFR inhibitor. Binimetinib works by blocking the activity of MEK, which prevents the growth of cancer cells.

Binimetinib, also known by the brand name Mektovi, is a prescription medication used in combination with another drug called encorafenib (Braftovi) to treat specific types of cancer:

• Unresectable or metastatic melanoma: This is a type of skin cancer that cannot be removed by surgery or has already spread to other parts of the body. Binimetinib is only used for melanoma with a specific genetic mutation called BRAF V600E or V600K.
• Metastatic non-small cell lung cancer (NSCLC): This is a type of lung cancer that has spread to other parts of the body. Binimetinib is again only used for NSCLC with the BRAF V600E mutation.